Media stories about Vital Therapies (NASDAQ:VTL) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vital Therapies earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.697547598997 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several research firms have issued reports on VTL. BidaskClub upgraded shares of Vital Therapies from a “hold” rating to a “buy” rating in a research report on Saturday, June 30th. ValuEngine upgraded shares of Vital Therapies from a “hold” rating to a “buy” rating in a research report on Friday, June 29th. BTIG Research reaffirmed a “hold” rating on shares of Vital Therapies in a research note on Monday, May 28th. Finally, Zacks Investment Research raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a research note on Saturday, May 12th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Vital Therapies presently has an average rating of “Buy”.
Shares of Vital Therapies traded down $0.93, hitting $7.68, during midday trading on Wednesday, Marketbeat.com reports. 363,547 shares of the stock traded hands, compared to its average volume of 248,180. The company has a market cap of $324.12 million, a price-to-earnings ratio of -5.86 and a beta of 4.20. Vital Therapies has a one year low of $2.42 and a one year high of $8.81.
About Vital Therapies
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.